News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 678 results
May 2015
-
Media ReleaseNovartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies- EXPEDITION trial results demonstrated QVA149 (indacaterol/glycopyrronium) met all primary and secondary endpoints(1),(2),(3),(4)- Treatment with QVA149 for 12 weeks provided robust dual…
-
Media ReleaseNovartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies
April 2015
-
Media ReleaseNovartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list- Reflects clear plan to embed diversity and inclusion in every aspect of our business from the company culture to our strategic business focus- Honor recognizes the passion and commitment of our…
-
Media ReleaseNovartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list
March 2015
-
Media ReleaseNovartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload- Jadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation- Jadenu, taken with or without food, simplifies daily treatment administration…
-
Media ReleaseNovartis announces FDA approval for Jadenu™ to simplify treatment administration for patients with chronic iron overload
-
Media ReleaseNovartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment- After two…
-
Media ReleaseNovartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients
-
Media ReleaseNew Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx™ (secukinumab) compared to Stelara® (ustekinumab) at Week 16- In…
-
Media ReleaseNew Novartis data show more Cosentyx™-treated psoriasis patients achieved clear or almost clear skin (PASI 90) compared to Stelara®
February 2015
-
Media ReleaseNovartis' heart failure medicine LCZ696 granted FDA priority review- Decision could speed access to LCZ696 for heart failure with reduced ejection fraction patients in the US, reducing total review time from 12 to 8 months(1) - Filing is based on results from the…
-
Media ReleaseNovartis' heart failure medicine LCZ696 granted FDA priority review
Pagination
- ‹ Previous page
- 1
- …
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- …
- 57
- › Next page